The World’s First Fetal Surgery Using Stem Cells for Spina Bifida
The first ever in utero stem cell treatment for spina bifida is the culmination of decades of work from UC Davis surgeon-scientist Diana Farmer. This novel fetal surgery at UC Davis Children’s Hospital could change the life of a developing baby with spina bifida, who otherwise could be born paralyzed from the waist down. This […]
Cell and Gene Therapy Companies Leverage GenScript’s cGMP sgRNA Capability to Accelerate Speed to Market
PISCATAWAY, N.J., Dec. 15, 2022 /PRNewswire/ — GenScript USA Inc., the world’s leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. GenScript’s 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials. “We are […]
Stem Cell Therapy for Autism – Liam’s Story
Meet Liam and his mother Brittany, they have been visiting the Innate Healthcare Institute the last few weeks for Liam’s stem cell therapy and he’s been doing great! Liam came to see Innate Healthcare to address a tendency to lose focus, a lack of attention, and also to improve his speech patterns. His mother describes […]
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
MELVILLE, N.Y., Dec. 06, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the […]
Lyell Immunopharma to Participate in BofA Securities Biotech Conference
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the virtual BofA Securities 2022 Biotech SMID Cap Conference on Thursday, Dec. 8 […]
2022 Ogawa-Yamanaka Stem Cell Prize Awarded to Juan Carlos Izpisua Belmonte – Award Ceremony
On November 17, 2022, Gladstone Institutes honored the 2022 Ogawa-Yamanaka Stem Cell Prize winner, Juan Carlos Izpisua Belmonte. Izpisua Belmonte is a celebrated scientist known for his regenerative medicine and aging research, as well as his work leading to improved methods of generating induced pluripotent stem cells (iPSCs). In a translational leap, his group was […]
reNEW | Next generation stem cell research
reNEW is a unique global collaboration focusing on stem cell research involving three leading research institutions: the University of Copenhagen in Denmark, the Leiden University Medical Center in the Netherlands, and the Murdoch Children’s Research Institute in Australia. reNEW’s vision is to create a new generation of effective, safe, and socially sustainable stem cell-based therapies […]
I Am ALS and Veterans with ALS send an Open Letter to FDA Requesting an Advisory Committee Meeting to Discuss NurOwn
WASHINGTON, Nov. 23, 2022 /PRNewswire/ — To the Honorable Dr. Robert Califf and Dr. Peter Marks: We represent Veterans with ALS who support Brainstorm Cell Therapeutics’ request for the FDA to hold a public Advisory Committee meeting (“AdCom”) to engage in scientific discourse about the “clinically meaningful” evidence supporting FDA’s approval of a mesenchymal stem cell therapy, NurOwn. When we […]
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera’s most advanced investigational drug, combines the proprietary molecule UM171 and an […]
ExCellThera announces 100th patient treated with UM171-expanded cell therapy
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]